Skip to main content

Table 2 Blocking BOLD signal changes following treatment with SRX251 and fluoxetine in response to aggressive promoting stimuli

From: Imaging the neural circuitry and chemical control of aggressive motivation

 

Volume of Activation

% Change in BOLD Signal

Brain Area

Mate/Intruder SRX251

Mate/Intruder Fluoxetine

Mate/Intruder SRX251

Mate/Intruder Fluoxetine

retrosplenial cortex (130)

12 (1, 47)

24 (9, 51)**

5.2 ± 0.3

10.4 ± 0.4

orbital cortex (45)

3 (0, 11)

5 (0, 6)

3.3 ± 0.2

2.0 ± 0.2

auditory cortex (98)

11 (0, 33)

13 (4, 38)

4.0 ± 1.7

4.3 ± 0.5

somatosensory cortex (599)

51 (1, 132)

117 (37, 233)**

3.8 ± 0.1

5.9 ± 0.4

motor cortex (386)

24 (0, 71)

57 (20, 181)**

3.7 ± 0.2

5.6 ± 0.2

visual cortex (212)

30 (3, 74)

38 (8, 101)

5.4 ± 0.5

7.6 ± 0.9

insular cortex (128)

4 (0, 14)

10 (4, 30)*

3.1 ± 0.2

3.4 ± 0.4

prelimbic cortex (32)

3 (0, 4)

5 (1, 11)

2.8 ± 0.1

2.5 ± 0.2

infralimbic cortex (17)

0 (0, 3)

5 (0, 9)**

2.0 ± 0.1

1.6 ± 0.1

anterior cingulate ctx (73)

6 (0, 15)

13 (1, 32)**

3.2 ± 0.1

3.6 ± 0.3

CA1 hippocampus (154)

10 (0, 44)

17 (2, 63)

2.9 ± 0.3

3.3 ± 0.2

dentate gyrus (100)

9 (0, 27)

9 (0, 44)

2.8 ± 0.3

3.0 ± 0.3

cortical n. amygdala (69)

6 (0, 24)

9 (3, 20)

3.3 ± 0.2

4.6 ± 0.4

basal n. amygdala (24)

1 (0, 3)

3 (0, 5)

2.3 ± 0.4

2.5 ± 0.2

central n. amygdala (13)

0 (0, 1)

0 (0, 2)

1.0 ± 0.1

0.9 ± 0.1

medial n. amygdala (14)

1 (0, 3)

2 (0, 7)

1.5 ± 0.4

2.7 ± 0.3

bed n. stria terminalis (15)

0 (0, 3)

3 (0, 7)

2.5 ± 0.2

2.7 ± 0.2

lateral post. n. thalamus (18)

1 (0, 5)

1 (0, 6)

1.9 ± 0.2

1.5 ± 0.1

anterior n. thalamus (12)

0 (0, 3)

1 (0, 4

1.0 ± 0.1

2.0 ± 0.3

substantia nigra (28)

1 (0, 6)

5 (0, 6)*

2.6 ± 0.1

3.7 ± 0.3

ventral tegmentum (16)

0 (0, 4)

2 (0, 5)

0.8 ± 0.2

1.8 ± 0.2

dorsal striatum (305)

12 (0, 39)

36 (5, 147)**

2.5 ± 0.2

2.2 ± 0.2

ventral pallidum (41)

1 (0, 5)

3 (0, 6)*

1.3 ± 0.2

2.0 ± 0.1

lateral hypothalamus (64)

5 (0,15)

8 (3, 15)

2.9 ± 0.3

3.3 ± 0.3

periaquedutcal gray (42)

4 (0, 15)

3 (0, 7)

1.9 ± 0.2

3.5 ± 0.6

raphe nuclei (15)

1 (0, 6)

1 (0, 2)

2.1 ± 0.4

0.8 ± 0.1

accumbens (45)

2 (0, 5)

8 (0, 25)**

2.8 ± 0.4

3.0 ± 0.2

PVN hypothalamus (3)

1 (0,2)

0 (0, 2)

1.8 ± 0.1

2.0 ± 0.1

  1. Shown are the median number of voxels (min, max) (i.e., volume of activation) and percent change in BOLD signal (mean ± SE) in different brain areas in response to aggressive motivation following SRX251 and fluoxetine treatment. These BOLD time course data were compared by taking the fifty data points following stimulus presentation for each condition and using a repeated measures 2-way ANOVA to assess if there was a significant difference between conditions. There were no significant differences in BOLD signal change over time between drug treatments. Significant differences in volume of activation between SRX251 and fluoxetine for each brain region are shown. The numbers in parenthesis shown after each brain area is the average number of voxels from ten subjects that occupy that brain volume after registration in the 3D atlas. Brain areas shown in bold italic comprise the putative neural circuit of aggressive motivation. p < 0.05*; p < 0.01**